B nucleus) is a semisynthetic antifungal antibiotic that possesses potent anti-Candida activity. The MICS0 and the MIC90 for both LY121019 and amphotericin B were 0.625 and 1.25 t g/ml, respectively.
Antifungal Agents LY121019 was prepared in the Lilly Research Laboratories. Amphotericin B and nystatin were obtained from E. R. Squibb and Sons. Miconazole was obtained from Janssen Pharmaceuticals. Clotrimazole was obtained from the Schering Corporation.
5-Fluorocytosine was obtained from Hoffmann-La Roche.
In Vitro Susceptibility Studies Candida albicans isolates were grown in Sabouraud's dextrose or Yeast Nitrogen Base (YNB) medium at 30°C. The procedures used for the agar dilution and broth dilution susceptibility tests were described previously3). MIC determinations were made at 48 hours.
In Vitro Resistance Development Tubes containing 5 ml YNB broth and doubling concentrations of LY121019 from 0.03980 jig/ml were prepared in triplicate. Each tube was inoculated with I >:101 log phase C. albicans A26 cells and incubated for 48 hours at 30°C. A 0.05 ml aliquot from the tube that contained the highest concentration of LY121019 that permitted growth was transferred to another series of tubes containing YNB broth with 2-fold dilutions of LY121019. A total of 17 serial transfers of C. albicans A26 were made in LY121019-containing medium, the 18th serial transfer was in LY121019 free medium.
Determination of Fungicidal Activity Inocula of I x 10° log phase cells of C. albicans A26 were added to tubes containing 5 ml YNB broth and concentrations of LY121019, amphotericin B, or nystatin ranging from 0.312~ 5.0 pp,g/ml. Following 48 hours incubation at 30°C, 0.1 ml aliquots were removed from each tube and plated on YNB agar plates. Fungicidal activity was determined as 99.9 % killing of C. albicans A26 following 48-hour exposure to the antifungal agents.
Effect of Antifungal Agents on Non-Metabolizing Cells of C. albicans LY121019, miconazole, or amphotericin B was added to YNB broth in tubes at 40 /<g/ml and diluted 2-fold to 0.078 tig/ml. 5 x 105 log phase cells of C. albicans A26 were added to 5 ml YNB broth containing antifungal agents. Inoculated tubes with or without antifungal agents were incubated at 4°C for 48 hours. The number of viable C. albicans A26 cells was determined from triplicate plate counts made on YNB agar after 48 hours incubation at 30°C.
Scanning Electron Microscopy YNB agar plates were prepared containing LY121019 at concentrations of 0.3, 0.75, 1.5 and 3 1(g/ml and a control plate without antibiotic. Nuclepore filters were placed on the agar surface and the plates were prewarmed to 30°C. Each filter was inoculated with 10 FBl of diluted culture to attain approximately 105 cells per filter. After incubation for 1, 3 or 5 hours, filter specimens were removed and placed in filter holders, rinsed with water and then fixed with 3 glutaraldehyde in cacodylate buffer for 1 hour. The specimens were then rinsed with 2 ml of buffer, dehydrated in ethanol, critical point dried in a Bomar apparatus and coated with gold in an Edward vacuum evaporator'.
Determination of ED;,, for Antifungal Agents against C. albicans The procedures used to determine the ED50 of LY121019 and amphotericin B in compromised mice were described previously4. CD, (Charles River) male mice weighing 18~20g were used. Ten mice were used for each concentration of antifungal agent tested. All antifungal agents were administered intraperitoneally at 0, 4 and 24 hours post-infection.
Recovery of C. albicans from Kidney Homogenates of Mice Treated with Antifungal Agents
The procedures used for recovering C. albicans from kidney homogenates of treated and untreated mice 24 hours following the last treatment were reported previously5). CD, mice were infected intravenously with 1 x 101 C. albicans A26 cells. Plate counts were made on YNB agar following incubation for 48 hours at 30°C.
Effect of Antifungal Agents on C. albicans Infections in the Gastrointestinal Tract of Mice
The procedures for establishing a Candida infection in the gastrointestinal tract of CD1 mice and subsequent treatment with antifungal agents were described previously6).
Effect of Antifungal Agents against Superficial C. albicans Infections The procedures for producing superficial C. albicans infections using albino guinea pigs (3505 00 g) were essentially the same as those reported previously7). Guinea pigs were inoculated on abraded skin with 1.0 ml of a saline suspension containing 2 x 107 cells/ml of C. albicans SC5314. The skin was gently abraded with a blunted 20 gauge needle in an overlapping horizontal and vertical pattern in an area approximately 25 x25 mm. The inoculum was then rubbed into the abraded area with a cotton swab. Topical treatment twice daily was started 5 days post-infection.
Two lesions were induced on each of two guinea pigs for each antifungal agent and controls. Lesion score (0~4) was determined subjectively on the degree of scaling, crusting, and erythema of superficial lesions.
Effect of Antifungal Agents against Rat Vaginal Candidiasis
The procedures used for establishing rat vaginal candidiasis were essentially the same as those reported previouslys'. In our studies, ovariectomized Wistar rats (Charles River) weighing 1702 00 g were treated subcutaneously for 7 days with 7.2 mg/kg of estradiol. Rats in estrus phase were inoculated intravaginally with I x 107 log phase cells of C. albicans SC9172. LY121019 was formulated in a modified vanishing cream base. Nystatin cream (Mycostatin, Squibb) and miconazole cream (Monostat, Johnson and Johnson) were used. Rats were treated intravaginally with approximately 0.1 ml of each cream formulation or placebo cream twice daily for 8 days. At 2 and 8 days post-treatment, the recovery of C. albicans was determined by plating triplicate 0.1 ml samples of a vaginal wash. Vaginal washes from rats held dorsal side down were obtained by introducing 0.05 ml of sterile saline into the vaginal cavity with a micropipet. The saline was aspirated several times to insure thorough washing of the vaginal cavity. The vaginal washes were removed from the vaginal cavity using a micropipet and diluted in 0.5 ml sterile saline before plating. Vaginal washes were obtained from 6 rats treated with each antifungal agent and the placebo, and from untreated controls. The plating procedure used was the same as that described for the recovery of C. albicans from kidney homogenates. The comparative effectiveness of each antifungal agent to the controls and each other was determined using the student "T" test.
Toxicology Evaluation LY12I019 was administered by intravenous infusion (25 mg/ml; 2.2 ml/minute) to groups of 2 male and 2 female beagle dogs at doses of 0, 10, 30 or 100 mg/kg/day, five days a week for three months. The vehicle consisted of 4.6 g NaH2PO4, 4.73 g Na2HPO4 and 4.8 g NaCl per liter of 33 % v/v polyethylene glycol 300 in distilled water. The vehicle was adjusted to pH 6.8 before use. Animals were examined daily for physical and behavioral signs of toxicity. Body weights were measured weekly. Hematology (leukocyte, erythrocyte, platelet, and reticulocyte counts, hemoglobin, packed cell volume, leukocyte differential, prothrombin time, erythrocyte morphology, fibrinogen, activated partial thromboplastin time), serum biochemistry (glucose, urea nitrogen, creatinine, total bilirubin, alanine transaminase, aspartate transaminase, alkaline phosphatase and lactate dehydrogenase), and urinalysis (pH, specific gravity, protein, glucose, occult blood and bilirubin) parameters were determined before the study began and at 1, 2, 7, 8 and 13 weeks. Concentrations of LY121019 in serum were determined by microbiological assay using Aspergillus nnontevidensis A35137 as the test organism. All serum or aqueous humor and cerebral spinal fluid samples were diluted 1: 1 with a solution of 50% methanol -50 pH 6.0 phosphate buffer. Petri plates (100 mm x 20 mm) were prepared containing 10 nil of Biochem Agar No. 3 medium with 0.3 nil of a standardized inoculum of A. montevidensis A35137. The Biochem Agar No. 3 medium consisted of the following: K._HPO; 0.69 g, KH2PO4 0.45 g, yeast extract 2.5 g, glucose 10.0 g, agar (purified) 20.0 g, distilled water to make 1,000 ml.
The standardized spore suspension was adjusted to 0.6 O.D. at 590 nm. Tobramycin (10 tig/ml) was added to the medium to prevent bacterial contamination.
Four 6 mm diameter agar wells were -ut from each plate in a symmetrical arrangement . A total 0.03 nil of serum sample was added to 2 agar wells and 2 agar wells received a reference point from the standard curve for LY121019. The Petri plates were incubated at 30'C for 48 hours. The potency of each sample was determined from a standard curve based on the zones of inhibition measured in millimeters. The sensitivity of this microbiological assay was 0.15 jig/ml of LY121019. Blood samples for serum were obtained at the end of the infusion, and 1/2, 1, 2, 4 and 6 hours later on the first day of dosing and at the same intervals after 1, 2 and 3 months treatment. On the last day of the study, dogs were dosed and samples of cerebral spinal fluid and aqueous humor collected for analysis of LY121019 content. At necropsy, liver, kidney, heart, adrenals, spleen, ovaries, testes and thyroid were removed and weighed. Bone marrow was obtained from ribs and processed for determination of the ratios of cells in the myeloid: erythroid series; body orifices, external and internal organs and tissues examined grossly. Specimens of the following organs and tissues were fixed and processed for histopathologic evaluation: kidney, liver, heart, lung, spleen, thymus, lymph node, salivary gland, pancreas, stomach, duodenum, jejunum, ileum, colon, ovary, uterus, adrenal, thyroid, testis, prostate, skin, mammary gland, skeletal muscle, urinary bladder, cerebrum, cerebellum, brain stem, pituitary, rib bone, rib bone marrow, eye, gallbladder and injection site (cephalic vein).
Results
In Vitro Susceptibility of C. albicans
The MIC's for LY121019 and amphotericin B against 96 C. albicans isolates are shown in Table 1 .
The MIC50 and MIC90 for LY121019, 0.625 and 1.25 jig/ml, were identical to those for amphotericin B, however, the range of MIC values for amphotericin B was broader than for LY121019.
Activity of Antifungal Agents on Different
Growth Media Using the Agar and Broth Dilution Tests Table 2 show that neither the test medium, In Vitro Resistance Development
The MIC of LY121019 for C. albicans A26 increased gradually from 0.625 leg/ ml to 5.0 leg/ml after 17 serial transfers in medium containing this agent. Following the 18th transfer in LY121019-free medium, the MIC was 2.5 leg/ml. Activity against Non-metabolizing C. albicans Cells Exposure of C. albicans A26 to 40 lrg LY121019/ml for 48 hours at 4'C did not affect viability (Fig. 2) . Exposure to similar concentrations of amphotericin B or miconazole effected decreases in viable cells of more than 2-logs and 1-log, respectively.
Scanning Electron Microscopic Study of Antifungal Action
When grown on a filter placed on the YNB medium, C. albicans A26, formed microcolonies of growing spherical and tubular shaped cells. These yeast cells formed a chain of interconnected or closely associated cells due to the budding process. The cell surfaces were generally smooth and featureless except for the button-like scar from the budding process (Fig. 3A) . The morphology of cells treated with LY121019 at 0.75 ,gag/ml or higher show changes as in Fig. 3B , treated with 1.5 l+g/ml for 3 hours.
No budding processes were observed and the center of the microcolony was covered with extracellular debris. The visible cells showed stringy attachments to other cells and small vacuoles on the cell surfaces. Some C. albicans A26 cells were partially collapsed.
ED50 Determinations
The ED50 of LY121019 for experimental systemic C. albicans infections in compromised mice shown in Table 3 was approximately 3-fold higher than the ED50 for amphotericin B.
Recovery of C. albicans from Infected Mouse Kidneys
Administration of 50 mg/kg doses of LY121019 or amphotericin B commencing 24 hours postinfection then daily for 5 days resulted in a greater than 3-log reduction in the numbers of C. albicans in kidney homogenates of systemically infected mice (Table 4) . When LY121019 administered at 4 hours preinfection, at the time of infection, and then daily for 5 days, doses of 12.5 and 25 mg/kg effected in a greater than 3-log reduction in numbers of C. albicans in kidney homogenates. Doses of 6.25 mg/kg LY121019 effected a 2-log reduction in the numbers of C. albicans.
Recovery of C. albicans from the Gastrointestinal Tract of Infected Mice
The activity of orally administered LY121019 or nystatin against C. albicans infections in the gastrointestinal tract of mice is summarized in Table 5 . Doses of 50 and 100 mg/kg LY121019 effected 
Activity against Superficial C. albicans Infections
The efficacy of 5% LY121019 or 3 % nystatin cream formulations against superficial C. albicans infections on guinea pigs is summarized in Table 6 . Lesion scores of LY121019 or nystatin treated animals compared with placebo and untreated, were reduced after 5 daily topical treatments. At 7 days post-treatment, superficial lesions on animals treated with either antifungal agent were cured.
In contrast, placebo-treated and untreated control animals showed little reduction in the scaling, crusting or erythema of cutaneous lesions.
Activity against Vaginal C. albicans Infections
The comparative efficacies of 3% LY121019, 2%, miconazole and 3% nystatin cream formulations against rat vaginal infections are presented in Table 7 . At 2 days post-treatment, local treatments of 3 LY121019, 2% miconazole or 3% nystatin resulted in a significant reduction (P<0.05) in the recovery of C. albicans from vaginal washes compared with placebo treated or untreated controls.
There was a significant difference (P<0.05) in the recovery of C. albicans between 2% miconazole and 3 % nystatin, but not between 3% LY12 1019 and 3 °o nystatin or 2 % miconazole. After 8 days of local treatments, the recovery of C. albicans, compared with placebo treated or untreated controls, was not significantly different between 3% LY121019 and 2% miconazole. However, the recovery of C. albicans with 3 % LY121019 treatments and 2% miconazole treatments were significantly different (P< 0.05) from the recovery obtained with 3%, nystatin treatments. The pre-and post-treatment MIC's Evaluation for Toxicity Outward manifestations of toxicity were encountered only in dogs given 100 mg LY121019/kg. As indicated in Table 8 , these dogs showed a 5 % weight loss and exhibited vasodilation, swelling and edema around the face and mouth, itching, a decrease in blood pressure, and tender, swollen and flaccid veins.
All of the above effects except for the effects on veins, were reversed one-half to three hours after dosing.
The clinical signs of toxicity were observed in some animals on the initial day of the study, occurred with variable severity in a given animal, and generally did not increase in severity as the study progressed.
Administration of LY121019 did not affect the formed elements of peripheral blood nor did it modify either physical or morphologic characteristics of urine. At doses of 100 mg/kg, but not at lower doses, LY121019 effected significant elevations of alkaline phosphatase and alanine transaminase at 1, 2, 4, 8 and 13 weeks (Fig. 4) . Other clinical chemistry parameters were not affected by this or lower doses of LY121019.
The concentrations of LY121019 in serum were directly related to the dose administered (Fig. 5) .
Concentrations at the end of the infusion ranged from 112-S 156, 344~622 and 558~1,064 11g/ml for dogs receiving daily doses of 10, 30 and 100 mg/kg, respectively. LY121019 was present in serum 6 hours in dogs that received 30 and 100 mg/kg doses. There was no evidence of accumulation or altered peak serum concentrations. Analysis of cerebral spinal fluid and aqueous humor for LY121019 1 for the three antifungal agents against C. albicans
were not greater than 2-fold.
hour after dosing indicated that LY121019 was not present in these fluids.
At necropsy, no LY121019-related effects on bone marrow were observed. As shown in Table 8 , analysis of organ weight data indicated an effect on liver weight. Relative liver weight was significantly increased for dogs from the 100 mg/kg group. LY121019-related lesions observed in the liver and at the site of injection are shown in Table 9 . A dose-related hemorrhage at the injection site was pre- sent only in dogs given LY121019. Inflammation occurred in some but not all dogs from each injected group including the vehicle control. More instances of inflammation were observed in dogs given 100 mg/kg than in other groups. Phlebitis of a focal nature occurred in the cephalic vein (site of injection) of one dog given 30 mg/kg/day and in two dogs given 100 mg/kg/day. Centrilobular fatty change was observed in hepatocytes from all dogs given 30 or 100 mg/kg. The change was mild and tended to be diffuse throughout the lobules in the 30 mg/kg dogs and marked in the 100 mg/kg dogs.
Discussion
LYI21019 showed potent in vitro activity that compared favorably with amphotericin B against a large number of C. albicans isolates. Furthermore, MIC values for LY121019 showed little variation when determined by the agar or broth dilution test using YNB or Sabouraud medium. In contrast to 5-fluorocytosine, the antifungal activity of LY121019 was unaffected by the nutrients in Sabouraud medium. Other properties of the in vitro antifungal activity include a fungicidal action at concentrations required for the MIC. Our studies indicate that LY121019 has a low potential for resistance development since the MIC for C. albicans increased only gradually 8-fold during 17 serial transfers in the presence of LY121019. The final transfer of C. albicans into LY121019-free medium showed only a 2-fold decrease in the MIC after exposure to LY121019. Whether or not this low level of resistance is stable remains to be determined.
Non-metabolizing cells of C. albicans were not inhibited by LY121019 whereas miconazole and amphotericin B showed increased MIC's against non-metabolizing cells at 4°C compared with MIC's obtained against normal metabolizing cells at 30°C. Because the mode of action of amphotericin B and miconazole are different from that of LY121019, this could account for the differential antifungal action of these agents. The mode of action of polyenes such as amphotericin B involves their irreversible binding to sterol components in cell membranes resulting in destruction of the membrane integrity").
In contrast, imidazoles such as miconazole inhibit the biosynthesis of sterol components of cell membranes resulting in cell leakage11). We have shown that LY121019 causes severe damage to the C. albicans cell wall. Echinocandin Band aculeacin are polypeptide antifungal antibiotics related to LY121019 that have been reported to inhibit the incorporation of glucan into the C. albicans cell wall12,13). The antifungal action of LY121019 requires actively metabolizing C. albicans cells, whereas the antifungal activity of polyene and imidazole antifungal agents against non-metabolizing cells is only decreased.
The in vitro anti-Candida activity of LY121019 correlated with in vivo efficacy. The ED50 obtained for LY121019 in the treatment of experimental systemic C. albicans mouse infections compared favorably with the ED50 obtained for amphotericin B. LY121019 was highly effective at doses of 12.5 and 25 mg/kg in reducing the recovery of C. albicans from kidneys. LY121019 administered orally was at least as effective as nystatin in eradicating C. albicans from the gastrointestinal tract of infected mice. Candida overgrowth in the gastrointestinal tract is known to be a predisposing factor of vaginal or systemic candidiasis. Agents that safely and effectively eliminate Candida colonized in the gastrointestinal tract would be useful in preventing the development of Candida infections. Topical application of LY121019 was as effective as nystatin against superficial C. albicans infections on guinea pigs. Further in vivo studies of the topical antifungal activity of LY121019 are needed to determine the optimum formulation and treatment regimen. There is a continuing need for antifungal agents that are effective against Candida infections of the skin, nails and especially chronic mucocutaneous candidiasis"). LY121019 administered intravaginally showed effectiveness comparable to clinically used agents such as nystatin and miconazole against rat vaginal candidiasis. Although vaginal candidiasis in many cases can be treated effectively by antifungal agents, this Candida infection can be intractable, recurrent, and become a distressing disease15). Clearly, more effective agents are needed for vaginal candidiasis.
The results of the toxicologic evaluation demonstrate that LY121019 can be safely given intravenously to dogs. Doses of 10, 30 or 100 mg/kg/day, five days per week for 13 weeks did not result in lethality or severe signs of toxicity. The serum concentrations of LY121019 detected during this study THE JOURNAL OF ANTIBIOTICS SEPT. 1984 indicated there was no accumulative toxicity. The absolute no-effect level was 10 mg/kg/day. Toxicity observed included hepatotoxicity as indicated by increases in alkaline phosphatase and alanine transaminase and histologic evidence of centrilobular fatty vacuolation; inflammation, hemorrhage, phlebitis and thrombosis at the injection site; and clinical signs of vasodilation, swelling around the face and mouth, edema, itching, and an apparent decrease in blood pressure. The clinical signs were thought to be indicative of an increase in circulating histamine levels. Subsequent preliminary experiments in the rat with intraperitoneal doses of LY121019 demonstrated that LY121019 can increase serum histamine levels. The hepatotoxicity observed was not accompanied by evidence of necrosis and, therefore, would have to be considered potentially reversible upon discontinuing LY121019 treatment.
The toxicity data for LY121019 compare very favorably with other studies on the toxicity of amphotericin B in dogs that showed doses of 2.5 mg/kg were not tolerated and doses of 1.25 mg/kg produced severe nephrotoxicity16).
LY121019 is a novel antifungal antibiotic that possesses potent in vitro activity against C. albicans. Furthermore, LY121019 showed significant effectiveness in experimental animal infections that are representative of a number of clinically important C. albicans infections. LY121019 was also welltolerated at doses required for in vivo efficacy in these experimental C. albicans infections. In addition, toxicity studies in dogs indicate that LY121019 is at least 20-fold less toxic than amphotericin B.
